Identifying and Assessing Burdens in Nonadvanced Systemic Mastocytosis

Target Audience 

The educational design of this activity addresses the needs of allergy/clinical immunology, gastroenterology, dermatology, and hematology clinicians who manage patients with nonadvanced systemic mastocytosis. 

Program Overview 

Nonadvanced systemic mastocytosis (SM) is a group of rare disorders characterized by mast cell accumulation that results in a significant and varied symptomatic burden to the patient. The most prevalent of these symptoms include gastrointestinal symptoms, dermatological symptoms, and recurrent anaphylaxis in response to a variety of triggers such as food, insect venom, and medications. In this Phone-a-Friend series, a multidisciplinary panel of faculty experts will address the importance of high-sensitivity assays to detect the KIT D816V mutation that is responsible for most cases of nonadvanced SM, the recently updated World Health Organization diagnostic criteria, the various triggers of mast cell activation, symptom assessment techniques, and patient education. The faculty will also discuss individualization of symptom-directed treatment strategies, evolving treatment options, and newly approved targeted therapies for the treatment of nonadvanced SM. 

Educational Objectives  

After completing this activity, the participant should be better able to: 

1. Evaluate patients with nonadvanced systemic mastocytosis to characterize symptoms, disease burdens, and results from ancillary testing 
2. Describe the mechanistic rationale and recent clinical trial evidence for new targeted treatment options in nonadvanced systemic mastocytosis

Physician Accreditation Statement 

Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation 

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.0 hours of pharmacology).

Global Contact Information 

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit 

In order to receive credit, participants must complete the following: 

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity. 
2. Complete the Preactivity Questions. 
3. Review the activity content. 
4. Achieve a grade of 70% or higher on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy 

There is no fee for this educational activity. 

Disclosures of Relevant Financial Relationships 

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.  

The faculty have the following relevant financial relationships with ineligible companies:

Tracy I. George, MD - Consulting fees: Allakos Inc, Blueprint Medicines Corporation, BluPrint Oncology Concepts, Celgene Corporation, CM Group Inc., E Squared Communications, Incyte Corporation, UBC (United BioSource LLC); Contracted Research: Blueprint Medicines Corporation, Celgene Corporation, Cogent Biosciences, Inc., Deciphera Pharmaceuticals, Inc., Incyte Corporation; all received by ARUP Laboratories

Matthew P. Giannetti, MD - Consulting fees: Blueprint Medicines, Cogent Biosciences; Contracted Research: Blueprint Medicines

The planners and managers from Global Education Group and Integritas Communications have no relevant financial relationships with ineligible companies to disclose. 

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.